Assembly Biosciences Inc. (NASDAQ: ASMB)
$14.5450
-0.1950 ( -1.72% ) 32.6K
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Market Data
Open
$14.5450
Previous close
$14.7400
Volume
32.6K
Market cap
$92.48M
Day range
$14.2850 - $15.3250
52 week range
$9.1212 - $19.9300
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 12 | Aug 08, 2024 |
s-8 | Registration statements | 4 | Aug 08, 2024 |
10-q | Quarterly Reports | 51 | Aug 08, 2024 |
4 | Insider transactions | 1 | Aug 05, 2024 |
4 | Insider transactions | 1 | Aug 05, 2024 |
4 | Insider transactions | 1 | Jul 08, 2024 |
sc | Insider transactions | 1 | Jun 24, 2024 |
4 | Insider transactions | 1 | Jun 20, 2024 |
sc | Insider transactions | 1 | Jun 20, 2024 |
424b5 | Other | 3 | Jun 18, 2024 |